Intranasal immunization with recombinant Lactococci carrying human papillomavirus E7 protein and mouse interleukin‑12 DNA induces E7‑specific antitumor effects in C57BL/6 mice

Li,Yijie; Li,Xinping; Liu,Huanhuan; Zhuang,Shuzhen; Yang,Jianhua; Zhang,Fuchun

doi:10.3892/ol.2013.1743

Intranasal immunization with recombinant Lactococci carrying human papillomavirus E7 protein and mouse interleukin‑12 DNA induces E7‑specific antitumor effects in C57BL/6 mice

Authors:
- Yijie Li
- Xinping Li
- Huanhuan Liu
- Shuzhen Zhuang
- Jianhua Yang
- Fuchun Zhang
View Affiliations

Affiliations: Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi, Xinjiang 830046, P.R. China
Published online on: December 9, 2013 https://doi.org/10.3892/ol.2013.1743
Pages: 576-582

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The use of Lactococcus lactis for the co‑delivery of antigens and cytokines has been shown to successfully induce a special immune response. However, it is unknown whether the same results may be triggered through immunization of animals with L. lactis simultaneously carrying protein antigen and cytokine DNA. The present study evaluated the protective effects of intranasally administered live L. lactis strains carrying human papillomavirus 16 E7 protein and murine interleukin‑12 (IL‑12) DNA (LL‑E7P‑IL‑12D) in a TC‑1 tumor animal model. C57BL/6 mice were intranasally immunized with recombinant lactococci, and assays for cytotoxicity measurement and tumor protection were carried out to assess the immunological effects of the vaccine candidates. IL‑12 and interferon‑γ serum levels were measured and immunization with LL‑E7P‑IL‑12D was shown to induce an E7‑specific immune response and to confer protection against TC‑1‑induced tumors in vivo. Mice in the LL-E7P-IL-12D group showed an 80% survival rate when the control mice had died. Therapeutic immunization with recombinant L. lactis strains 7 days after TC‑1 injection led to a reduction in the number of palpable tumors in treated mice. The antitumor effects of the vaccination occurred through an E7‑specific cytotoxic T‑lymphocyte response. In the present study, the use of a single L. lactis strain, to co‑administer protein antigen and adjuvant DNA, successfully induced an antigen‑specific immune response. These observations demonstrate a new strategy for the use of L. lactis as a delivery vector of therapeutic molecules and antigens.

View Figures

View References

1	Mitragotri S: Immunization without needles. Nat Rev Immunol. 5:905–916. 2005. View Article : Google Scholar : PubMed/NCBI
2	Holmgren J and Czerkinsky C: Mucosal immunity and vaccines. Nat Med. 11(Suppl 4): S45–S53. 2005. View Article : Google Scholar : PubMed/NCBI
3	Neutra MR and Kozlowski PA: Mucosal vaccines: the promise and the challenge. Nat Rev Immunol. 6:148–158. 2006. View Article : Google Scholar : PubMed/NCBI
4	Bermúdez-Humarán LG, Kharrat P, Chatel JM and Langella P: Lactococci and lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccines. Microb Cell Fact. 10(Suppl 1): S42011.PubMed/NCBI
5	Bahey-El-Din M: Lactococcus lactis-based vaccines from laboratory bench to human use: an overview. Vaccine. 30:685–690. 2012. View Article : Google Scholar
6	Wells JM and Mercenier A: Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat Rev Microbiol. 6:349–362. 2008. View Article : Google Scholar : PubMed/NCBI
7	Moorthy G and Ramasamy R: Mucosal immunisation of mice with malaria protein on lactic acid bacterial cell walls. Vaccine. 25:3636–3645. 2007. View Article : Google Scholar : PubMed/NCBI
8	Villa LL, Costa RL, Petta CA, et al: Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 6:271–278. 2005. View Article : Google Scholar
9	Hildesheim A, Herrero R, Wacholder S, et al: Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA. 298:743–753. 2007. View Article : Google Scholar : PubMed/NCBI
10	Boulet G, Horvath C, Vanden Broeck D, Sahebali S and Bogers J: Human papillomavirus: E6 and E7 oncogenes. Int J Biochem Cell Biol. 39:2006–2011. 2007. View Article : Google Scholar
11	Bermúdez-Humarán LG, Cortes-Perez NG, Lefèvre F, et al: A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors. J Immunol. 175:7297–7302. 2005.
12	Jin HS, Park EK, Lee JM, et al: Immunization with adenoviral vectors carrying recombinant IL-12 and E7 enhanced the antitumor immunity to human papillomavirus 16-associated tumor. Gynecol Oncol. 97:559–567. 2005. View Article : Google Scholar
13	Lin CT, Tsai YC, He L, et al: DNA vaccines encoding IL-2 linked to HPV-16 E7 antigen generate enhanced E7-specific CTL responses and antitumor activity. Immunol Lett. 114:86–93. 2007. View Article : Google Scholar : PubMed/NCBI
14	Hibbitts S: TA-CIN, a vaccine incorporating a recombinant HPV fusion protein (HPV16 L2E6E7) for the potential treatment of HPV16-associated genital diseases. Curr Opin Mol Ther. 12:598–606. 2010.PubMed/NCBI
15	Wick DA and Webb JR: A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors. Vaccine. 29:7857–7866. 2011. View Article : Google Scholar
16	Lin KY, Guarnieri FG, Staveley-O'Carroll KF, et al: Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56:21–26. 1996.
17	Zhang M, Zhang F, Jian X, et al: Cloning and mutation of human papillomavirus type 16 (Xinjiang strain) E7 gene. Biotechnology. 13:4–6. 2003.(In Chinese).
18	Tao L, Pavlova SI, Ji X, Jin L and Spear G: A novel plasmid for delivering genes into mammalian cells with noninvasive food and commensal lactic acid bacteria. Plasmid. 65:8–14. 2011. View Article : Google Scholar : PubMed/NCBI
19	Li YJ, Liu HH and Zhang FC: Co-delivery of exogenous protein and DNA into mammalian cells with Lactococcus lactis. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 28:1328–1330. 2012.(In Chinese).
20	Audibert F: Adjuvants for vaccines, a quest. Int Immunopharmacol. 3:1187–1193. 2003. View Article : Google Scholar : PubMed/NCBI
21	Dubensky TW Jr and Reed SG: Adjuvants for cancer vaccines. Semin Immunol. 22:155–161. 2010. View Article : Google Scholar : PubMed/NCBI
22	Steidler L, Robinson K, Chamberlain L, et al: Mucosal delivery of murine interleukin-2 (IL-2) and IL-6 by recombinant strains of Lactococcus lactis coexpressing antigen and cytokine. Infect Immun. 66:3183–3189. 1998.
23	Guimarães VD, Innocentin S, Lefèvre F, et al: Use of native lactococci as vehicles for delivery of DNA into mammalian epithelial cells. Appl Environ Microbiol. 72:7091–7097. 2006.PubMed/NCBI
24	Gram GJ, Fomsgaard A, Thorn M, Madsen SM and Glenting J: Immunological analysis of a Lactococcus lactis-based DNA vaccine expressing HIV gp120. Genet Vaccines Ther. 5:32007.
25	Innocentin S, Guimarães V, Miyoshi A, et al: Lactococcus lactis expressing either Staphylococcus aureus fibronectin-binding protein A or Listeria monocytogenes internalin A can efficiently internalize and deliver DNA in human epithelial cells. Appl Environ Microbiol. 75:4870–4878. 2009. View Article : Google Scholar
26	Li YJ, Li Xinping and Zhang FC: The effects of Lactococcus lactis carrying the interleukin-12 (IL-12) gene or recombinant IL-12 protein via different routes mediated antitumor activity. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 29:392–395. 2013.(In Chinese).
27	Cortes-Perez NG, Lefèvre F, Corthier G, Adel-Patient K, Langella P and Bermúdez-Humarán LG: Influence of the route of immunization and the nature of the bacterial vector on immunogenicity of mucosal vaccines based on lactic acid bacteria. Vaccine. 25:6581–6588. 2007. View Article : Google Scholar
28	Bermúdez-Humarán LG, Cortes-Perez NG, Le Loir Y, et al: An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci. J Med Microbiol. 53:427–433. 2004.
29	Leonard JP, Sherman ML, Fisher GL, et al: Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood. 90:2541–2548. 1997.PubMed/NCBI
30	Huber VC, Arulanandam BP, Arnaboldi PM, et al: Delivery of IL-12 intranasally leads to reduced IL-12-mediated toxicity. Int Immunopharmacol. 3:801–809. 2003. View Article : Google Scholar : PubMed/NCBI